Professor Kevin Moore
Group Scientific Lead - Hepatology
Professor Kevin Moore is an expert in liver disease with over twenty years of experience working as a consultant in liver transplantation and general hepatology. He trained in medicine at King’s College London where he also obtained a BSc and PhD in Biochemistry. He is triply accredited in hepatology, general internal medicine as well as Clinical Pharmacology and Therapeutics. He continues to work as an acute physician. He is Professor of Hepatology at UCL and undertakes his clinical work at the Royal Free London NHS Foundation Trust.
As a hepatologist he sees patients with a wide range of liver diseases. He has a strong background in all aspects of general hepatology including alcohol misuse disorders, fatty liver disease as well as a prior 20 year experience of looking after liver transplant patients. As a biochemist Professor Moore has extensive analytical experience using biological mass spectrometry (GCMS and LCMS), as well as experience of many physiological and pharmacological techniques. Formerly, Professor Moore was Associate Editor of GUT, Free Radical Biology and Medicine as well as the American Journal of Pathology, which reflects the wide range and diversity of his expertise.
Professor Moore co-wrote the Oxford Handbook of Acute Medicine, as well as the Oxford Desk Reference of Acute Medicine. He chaired the writing of the National Plan for Liver Services in 2010 and has been widely published in numerous peer-reviewed journals with an H Index of 60+. Professor Moore is the Course Director for the Applied Medical Science undergraduate programme, which he founded in 2013, and which now has more than 400 students.
Richmond Research Institute benefits from Professor Moore’s extensive experience. Liver related research at the institute includes studying the detection and impact of liver abnormalities, such as fatty deposits, on drug metabolism and how dietary composition can influence the detection of hepatotoxicity. This work aims to improve clinical trial design and methods to better detect and screen out individuals with pre-existing liver abnormalities. This in turn should reduce the potential for misleading results.